SG11202001439QA - Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis - Google Patents

Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis

Info

Publication number
SG11202001439QA
SG11202001439QA SG11202001439QA SG11202001439QA SG11202001439QA SG 11202001439Q A SG11202001439Q A SG 11202001439QA SG 11202001439Q A SG11202001439Q A SG 11202001439QA SG 11202001439Q A SG11202001439Q A SG 11202001439QA SG 11202001439Q A SG11202001439Q A SG 11202001439QA
Authority
SG
Singapore
Prior art keywords
adenomyosis
pharmaceutical formulations
solid pharmaceutical
polycystic ovary
ovary syndrome
Prior art date
Application number
SG11202001439QA
Other languages
English (en)
Inventor
Yihong Qiu
Yuchuan Gong
Alexander RUGGLES
Jared A Baird
Kristof Chwalisz
Charlotte D Owens
James W Thomas
Jane Castelli-Haley
Keith Gordon
Michael C Snabes
Ahmed M Soliman
Oscar Antunez Flores
Rita Jain
Juki Wing-Keung Ng
Janine D North
Hannah Palac
Paul M Peloso
Laura A Williams
hui Zu
Yuerong Hu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/043321 external-priority patent/WO2019203870A1/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority claimed from PCT/US2018/047073 external-priority patent/WO2019036713A1/en
Publication of SG11202001439QA publication Critical patent/SG11202001439QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202001439QA 2017-08-18 2018-08-20 Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis SG11202001439QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762547410P 2017-08-18 2017-08-18
US201862660104P 2018-04-19 2018-04-19
PCT/US2018/043321 WO2019203870A1 (en) 2018-04-19 2018-07-23 Methods of treating heavy menstrual bleeding
PCT/US2018/047073 WO2019036713A1 (en) 2017-08-18 2018-08-20 SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS

Publications (1)

Publication Number Publication Date
SG11202001439QA true SG11202001439QA (en) 2020-03-30

Family

ID=69636712

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001439QA SG11202001439QA (en) 2017-08-18 2018-08-20 Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis

Country Status (10)

Country Link
EP (1) EP3668514A4 (zh)
JP (1) JP7350715B2 (zh)
KR (1) KR20200053502A (zh)
CN (1) CN111246850A (zh)
AU (1) AU2018317473A1 (zh)
BR (1) BR112020003388A2 (zh)
CA (1) CA3073247A1 (zh)
IL (1) IL272682A (zh)
MX (2) MX2020001874A (zh)
SG (1) SG11202001439QA (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112494425B (zh) * 2020-12-14 2023-06-23 珠海优润医药科技有限公司 一种恶拉戈利钠口服溶液及其制备方法
WO2022222886A1 (zh) * 2021-04-21 2022-10-27 上海启晟合研医药科技有限公司 一种噁拉戈利钠组合物
CN113876728B (zh) * 2021-11-17 2022-12-13 南京唯创远医药科技有限公司 一种噁拉戈利冻干片及其制备方法
CN114948889A (zh) * 2022-06-17 2022-08-30 哈药集团技术中心 一种噁拉戈利片的制备方法及其制备的噁拉戈利片
CN115804774A (zh) * 2022-08-26 2023-03-17 济川(上海)医学科技有限公司 一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用
CN116459225B (zh) * 2023-04-26 2023-11-10 东莞市金美济药业有限公司 一种艾拉戈克钠片及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065309A1 (en) * 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
WO2009062087A1 (en) * 2007-11-07 2009-05-14 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
CA2723558A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
EP2968566A1 (en) * 2013-03-15 2016-01-20 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding and uterine fibroids
CN113081991B (zh) * 2015-06-03 2022-07-15 南京三迭纪医药科技有限公司 药品剂型及其使用
US20190321363A1 (en) * 2016-06-20 2019-10-24 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph
WO2018224063A2 (en) * 2017-06-08 2018-12-13 Zentiva, K.S. Solid forms of elagolix

Also Published As

Publication number Publication date
IL272682A (en) 2020-03-31
KR20200053502A (ko) 2020-05-18
MX2020001874A (es) 2020-09-14
EP3668514A4 (en) 2021-07-14
JP2020531475A (ja) 2020-11-05
CN111246850A (zh) 2020-06-05
JP7350715B2 (ja) 2023-09-26
AU2018317473A1 (en) 2020-03-05
CA3073247A1 (en) 2019-02-21
MX2023002449A (es) 2023-03-22
EP3668514A1 (en) 2020-06-24
BR112020003388A2 (pt) 2020-08-25

Similar Documents

Publication Publication Date Title
IL272682A (en) Solid pharmaceutical formulations for the treatment of endometriosis, uterine fibroids and polycystic ovary syndrome and adenomyosis
IL272723A (en) Pharmaceutical formulations for the treatment of endometriosis, uterine fibroids and polycystic ovary syndrome and adenomyosis
IL272748B (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use
SG11202104687SA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
SG11202104686QA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
IL283109A (en) System and methods for multi-chamber and multi-spray vaporizers
IL272570A (en) Methods and preparations for the detection and treatment of endometriosis
EP3725027C0 (en) DEVICE WITH PHYSICALLY NON-CLONABLE FUNCTION
HK1250627A1 (zh) 用於治療hcv的固體藥物組合物
PL3585709T3 (pl) Ulepszony przenośnik prętowy
GB2562230B (en) Thermal encapsulation apparatus
HK1255203A1 (zh) 用於治療hcv的固體藥物組合物
HK1252415A1 (zh) 包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2，6-二酮的藥物組合物
KR102188387B9 (ko) 지연을 이용하는 레이더 장치
ZA201905262B (en) An agent for promoting angiogenesis and methods and uses thereof
HUE063583T2 (hu) Berendezés két vagy több komponens összekeverésére és eljárás ilyen berendezés kalibrálására
EP3619317A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ENDOMETRIOSIS AND SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS
HUE065294T2 (hu) Késleltetett nyújtott hatóanyag-leadású gyógyszerkészítmények
GB201917109D0 (en) Device for the determination of fertility status
IL256012B (en) A process and facility for the production of a nutritious inorganic iron preparation
GB201703108D0 (en) Restraining means
GB201517115D0 (en) Compounds, compositions and methods for authenticating products
HUP1600088A2 (en) Intrauterine contraceptive device